Diagnosing the severity of dry eye: a clear and practical algorithm

Christophe Baudouin,1,2,3 Pasquale Aragona,4 Gysbert Van Setten,5 Maurizio Rolando,6 Murat Irkeç,7 José Benítez del Castillo,8 Gerd Geerling,9 Marc Labetoulle,10 Stefano Bonini,11 ODISSEY European Consensus Group members

ABSTRACT
Dry eye disease (DED) is a distressing ocular condition. Due to its multifactorial nature, clinical and biological signs of DED can be inconsistent and sometimes discordant with symptomatology. Consequently, no gold-standard model for determining DED severity exists. This can impact treatment decisions and complicate evaluation of disease progression, particularly within the stringent context of clinical trials. The multinational ODISSEY European Consensus Group is comprised of ophthalmologists who contend with ocular surface disease issues on a daily basis. This group convened to establish a clear and practical algorithm for evaluation and diagnosis of severe DED. Using a consensus-based approach, they assessed 14 commonly used DED severity criteria. The panel agreed that following confirmed DED diagnosis, just two criteria, symptom-based assessment and corneal fluorescein staining were sufficient to diagnose the presence of severe DED in the majority of patients. In the event of discordance between signs and symptoms, further evaluation using additional determinant criteria was recommended. This report presents the ODISSEY European Consensus Group recommended algorithm for DED evaluation, which facilitates diagnosis of severe disease even in the event of discordance between signs and symptoms. It is intended that this algorithm will be useful in a clinical and developmental setting.

INTRODUCTION
Dry eye disease (DED) is a common ocular condition which significantly reduces quality of life, and affects 6–34% of the global adult population.1–2 Pathological dry eye was first described as keratoconjunctivitis sicca (KCS) over 70 years ago,3–5 and although DED and KCS are not strictly synonymous (as DED can present without keratitis6), this report will follow accepted dogma by assuming that the terms DED and KCS are interchangeable, and adopt the following 2007 International Dry Eye Workshop (DEWS) definition:

Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.6

There are relatively few effective treatments for DED, especially for severe disease.7 Clinical development of new DED treatments is slow, partly because of problematic diagnosis and classification.8 DED pathogenesis and presentation is multifarious, and symptomatology and signs of DED can be inconsistent. Many disease severity criteria currently used by ophthalmologists are confounded by complex disease subtypes and a lack of standardisation, and the selection of single criteria for assessment of disease severity is therefore fraught with difficulties.9–11 This lack of dependable diagnostic criteria for disease progression and therapeutic response can undermine clinical trial success and complicate clinical decision making.8 11–13

The vicious circle of disease progression
Numerous extrinsic and intrinsic factors can trigger DED by negatively impacting tear film stability and tear hyperosmolarity; activating osmotic/mechanical stress mechanisms.14–17 This leads to apoptosis, ocular cell damage, and release of inflammatory mediators, increasing ocular surface stress and leading to potential epithelial damage.18 19 Chronic inflammatory response is now thought to be one of the most important mechanisms in DED pathogenesis.20–22

In the early stages of mild or moderate DED, the eye can adapt and introduce compensatory mechanisms, and the condition will respond to treatment.23 However, if initial damage is prolonged or too severe, goblet cell repair mechanisms can falter and mucin production becomes dysregulated. Altered mucin production can reduce tear film stability, and a deadly feedback loop of escalating inflammation can manifest. This cycle has been termed the ‘vicious circle’ (figure 1B). No matter how the cycle starts, once it establishes it can lead to severe treatment-refractory disease and permanent damage if no corrective treatment is given.22 23

Discordance between DED signs and symptoms
Many DED pathophysiological mechanisms stimulate sensory neurons of the cornea, and DED has sometimes been described as a ‘symptomatic disease’.24–26 For the majority of DED patients, there is some relation between symptoms and clinical signs. However, it is also well established that perceived symptom severity may not equate to clinical signs of disease, and there exists a significant proportion of patients who have seemingly conflicting signs and symptoms.10 25 27 Indeed, one study showed that up to 40% of patients had symptom and clinical sign discordance.12 Another study showed meibomian gland disease was more commonly asymptomatic than symptomatic (21.9% vs 8.6%, respectively), and symptom presentation did not correlate with severity of ocular surface damage.28 Physiological mechanisms can partly account for these discrepancies.22 29
In early or mild DED, the presence of hyperalgesia can cause significant ocular discomfort without any signs of tissue damage. Yet in more severe or chronic disease, decreased corneal sensation due to compensatory reflex mechanisms can actually reduce discomfort. Corneal sensory neurons can sometimes also be permanently damaged by very severe DED, or by the underlying causal disease leading to DED.

In addition to the physiological explanation of discordance, the variable specificity, sensitivity and reproducibility of some clinical/biological marker evaluations can introduce the potential for false results. This may also confound severity assessments and contribute to supposed symptom and sign discordance. In one study, over 60% of patients remained poorly classified in terms of disease severity even when a combination of clinical markers was applied. This apparent paradoxical disconnect between signs, symptoms and severity makes symptomatology alone a relatively poor indicator of severity in some patients, and also a confounding variable in clinical trials.

**Evaluation of DED severity**

There is still no gold-standard model for determining DED severity. In 2006, a Delphi panel of DED specialists agreed that disease severity is one of the most relevant factors when considering therapeutic options for DED. They subsequently recommended a DED severity grading which was later adopted by the DEWS. Severity was categorised into four levels, based on increasing frequency and intensity of various signs and symptoms. Patient-reported symptoms included requirement of tear substitute, ocular discomfort and visual disturbance. Clinical signs included conjunctival injection, conjunctival and corneal staining, corneal/tear signs (ie, filamentary keratitis), lid/meibomian glands, tear break-up time (TBUT; fluorescein based), and Schirmer score. This system is advantageous in terms of simplicity and practicality, but requires severe symptoms AND severe signs before severe disease is diagnosed. Therefore, this algorithm may not be suitable for patients whose signs and symptoms do not concur. The aim of this consensus group was to build on the DEWS methodology and optimise tailored diagnostic methods specifically for severe DED.

**THE ODISEY EUROPEAN CONSENSUS GROUP**

An algorithm that identifies the criteria most relevant to the patient will allow for targeted evaluation of the ocular surface and facilitate assessment of disease severity. This ‘bespoke’ approach to evaluation of severe DED will help to define the most appropriate treatment in the clinical setting, and will also allow for better designed clinical trials. With this aim in mind, the ODISEY European Consensus Group, comprising 10 ophthalmologists (including one American) who all contend with ocular surface disease issues on a daily basis, was formed.

Members were first asked to complete an electronic questionnaire aimed at finding out which clinical and biological criteria they thought were important for diagnosing severe DED. They then attended a day-long meeting in September 2012. The aim of this meeting was to review clinical and scientific challenges in diagnosis and management of severe DED, and to achieve consensus agreement on a simplified approach to severe DED evaluation. A total of 14 criteria for DED severity were discussed. Advantages and issues were addressed, and also their specificity and sensitivity for diagnosing severe DED. Appropriate scales of assessment and reference values for each criterion were also suggested, based on clinical judgement and the literature.

The following markers and evaluations were discussed:

- Corneal fluorescein staining (CFS)
- Tear hyperosmolarity
- Schirmer test
- Impression cytology
- Filamentary keratitis
- Conjunctival staining
- Impaired visual function
- Meibomian gland disease or eyelid inflammation
- Blepharospasm
- TBUT
- Aberrometry
- In vivo corneal confocal microscopy
A SIMPLIFIED AND PRACTICAL APPROACH TO EVALUATING DED SEVERITY

Following extensive review of current knowledge, questionnaire results analysis and discussion, the ODISSEY European Consensus Group defined a two-step scoring algorithm for diagnosing severe DED (figure 2). The algorithm addresses the challenge of symptom and sign discordance in some cases of severe DED, and describes specific criteria relevant to evaluating DED severity in three different patient scenarios.

Step 1: fundamentals of severe DED diagnosis

The first step of the scoring algorithm evaluates the minimum number of fundamental criteria required for severe DED diagnosis. It was recommended by the panel that just two criteria, a symptomatic assessment and an evaluation of ocular surface damage by CFS would be sufficient to adequately evaluate severity for the majority of patients. These two criteria are discussed below.

Symptomatology and CFS as the primary assessment criteria

DED symptoms of ocular discomfort and visual disturbance can seriously impact patients’ quality of life.25 The Food and Drug Administration (FDA) has emphasised the importance of patient-reported outcomes as clinical endpoints in ophthalmological trials,34 and a number of validated questionnaires have been developed to assess symptoms of dry eye.35–38 These tools are generally economically viable, correlate well with quality of life, have good sensitivity for DED diagnosis, and can be easily quantified. However, the panel also acknowledged that symptom assessments may not be easily reproducible, are not necessarily specific for DED, and their use may carry a risk of overtreatment.

The Ocular Surface Disease Index (OSDI) is one of the most widely used questionnaires. The OSDI and similar tools have been shown to correlate moderately well with visual acuity and disease severity.8–9 CFS requires a standardised assessment procedure; also no method of objective quantification is available. However, a score ≥3 on the Oxford Scheme generally indicates severe DED.14 It must also be remembered that CFS will stain all corneal damage non-specifically, irrespective of cause (eg, refractive laser surgery and drug toxicity).41

Ambiguous, asymmetrical and artefact staining patterns can also be an issue, as can sensitivity in mild disease (similar to all known markers of DED).9 13 29

Following discussion, ODISSEY members decided that combined use of CFS and symptom-based assessment can provide a reliable ‘frontline’ diagnostic approach for evaluation of DED severity, and that an OSDI score ≥33 and CFS score ≥3 on the Oxford Scheme is enough to clearly establish a diagnosis of severe DED in those patients whose signs and symptoms of disease associate well. Thus, it was recommended that these criteria should be adopted for Step 1 of the diagnostic algorithm (figure 2). However, in cases of discordance, it was recommended that further additional evaluations are needed in order to improve diagnostic specificity.

Step 2: additional criteria for severe DED diagnosis

The panel agreed that when there is discordance between DED signs and symptoms, that is, when OSDI and CFS severity scorings are not in agreement, additional criteria are necessary to establish severe DED. Three possible outcomes after CFS and OSDI assessment in Step 1 were defined:

▸ Scenario A: if OSDI<33 and CFS≥3. Symptomatology is not indicative of severe disease despite severe ocular surface damage.

▸ Scenario B: if OSDI≥33 and CFS=2. Symptomatology is severe, but ocular surface damage is borderline or inconclusive.

▸ Scenario C: if OSDI≥33 and CFS≤1. Symptomatology is severe, but ocular surface damage is not particularly evident. The disposition of each patient in Step 2 (ie, Scenario A, B, or C) determines the additional criteria recommended to further evaluate DED severity.

The clinical and biological signs were divided by the panel into two groups. Each criterion was labelled as either being ‘determinant’ or ‘contributory’ to diagnosis of severe DED. A summary of the issues discussed by the panel with regards to each criterion is outlined in table 1 for criteria defined as determinant, and table 2 for criteria defined as contributory.
<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Advantages</th>
<th>Issues</th>
<th>Assessment parameters</th>
<th>Severe disease criteria</th>
</tr>
</thead>
</table>
| Conjunctival staining (including conjunctivochalasis/conjunctival folds) | ▶ Staining is related to epithelial damage.  
▶ Easy to perform.  
▶ Good reproducibility (once examiner is fully trained).  
▶ Already existing grading scales.  
▶ Standard method is cost and time effective. | ▶ Epithelial damage is not correlated with subjective signs and improvement.  
▶ Easy to overestimate or underestimate findings.  
▶ Potential interexaminer variability.  
▶ Many assessment scales available.  
▶ Yellow filter may be expensive (and red filter is often not easily available).  
▶ May need 2–3 min time window before correct assessment can be made. | Yes/no for presence of severe disease, as determined on any standardised scale (ie, Oxford Scheme) | Yes, has severe disease as measured on scale |
| Schirmer Test Quantitative test for tear fluid availability. Measures maximal tear secretion capacity without anaesthesia. | ▶ Well established.  
▶ Easy to use.  
▶ Commonly accepted and available.  
▶ Safe and efficient.  
▶ Well tolerated (except with severe DED). | ▶ There is discussion regarding specificity and sensitivity.  
▶ Dependent on corneo-conjunctival sensitivity, normal reflex regulations, uneven wetting of paper.  
▶ Issues with reproducibility (ie, environmental factors).  
▶ Issues with interpretation (ie, cut-off point).  
▶ Issue with comparability (ie, variation of size, colour code, paper).  
▶ Unknown effects of tear fluid composition (lipid layer alterations). | Continuous measurement—cut-off criteria for severe disease | <3 mm |
| Impaired visual function | ▶ Non-invasive technique.  
▶ Information is easy to obtain from the patient.  
▶ Can be self-administered by the patient  
▶ Non-expensive.  
▶ Can easily be part of standard patient work-up.  
▶ Easily repeatable in controlled conditions.  
▶ Can be used to monitor progression. | ▶ Subjective.  
▶ External bias and confounding factors.  
▶ Non-specific.  
▶ Global tear film stability index.  
▶ Cannot distinguish tear instability effects from cornea surface damage. | Yes/no | Yes |
| Filamentary keratitis Characterised by degenerated fragments of corneal epithelial cell and mucus firmly attached to the corneal surface. | ▶ Highly symptomatic.  
▶ Good correlation with severity.  
▶ Diagnosis is easy for general ophthalmologist.  
▶ Small number of patients for clinical trials and brief course of treatment may allow a fast evaluation of results. | ▶ Non-specific for dry eye.  
▶ Small number of patients with difficult recruitment.  
▶ Medical treatment may not be sufficient. | Yes/no | Yes |
| Tear hyperosmolarity Thought to be a central mechanism of tissue damage in DED. | ▶ The most valuable single metric for diagnosis and disease management.  
▶ A global marker for DED.  
▶ Parallels disease severity.  
▶ Responds to effective therapy. | ▶ Not yet widely available.  
▶ Must distinguish between the subtypes of DED with other tests.  
▶ Symptom improvement may lag behind tear osmolarity improvement.  
▶ Needs an external laboratory experienced in cytology and an observer trained in conjunctival pathologies.  
▶ Assessment of squamous metaplasia only | Continuous measurement—cut-off criteria for severe disease | >328 mOsm/L |
| Impression cytology Conjunctival epithelium sampling method for use with immunocytology and histology | ▶ Minimally invasive.  
▶ Well validated with published scoring systems.  
▶ Goblet cell count as an objective marker. | ▶ Nelson scale—cut-off criteria for severe disease | ≥Grade 3 |

Continued
### Table 1 Continued

<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Advantages</th>
<th>Issues</th>
<th>Assessment parameters</th>
<th>Severe disease criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Severe disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diagnostic test</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Advantages</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Issues</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Assessment parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Severe disease criteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Determinant factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contributory criteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other contributory factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

These are clinical and biological markers or evaluations considered by the ODYSSEY consensus panel as being sufficiently validated to establish diagnosis of severe DED.

DED, dry eye disease; DEWS, dry eye workshop; KCS, keratoconjunctivitis sicca; mOsm, milliosmole; TBUT, tear break-up time.

---

**Example Text:**

- **Specimens can be stored for a long period of time before processing.**
- **No major technical issue with standard cytological techniques.**

**Issues:**

- **Impression cytology provides only a small amount of possible information from biological specimens.**

**Assessment parameters:**

- **Yes/no**
- **Yes**

---

**Example Table:**

<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Advantages</th>
<th>Issues</th>
<th>Assessment parameters</th>
<th>Severe disease criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blepharospasm</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secondary to ocular irritation.</strong></td>
<td>Good marker for severe DED.</td>
<td>Patients can have similar complaints as with DED.</td>
<td>Yes/no</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Meibomian gland disease or eyelid inflammation</strong></td>
<td>Easy to diagnose (only if more severe/significant).</td>
<td>Subtle initial signs and stages, often not recognised.</td>
<td>Yes/no to a severe degree</td>
<td>Yes</td>
</tr>
</tbody>
</table>

---

**Example Text:**

- **Blepharospasm**
  - Good marker for severe DED.
  - Secondary to ocular irritation.

- **Meibomian gland disease or eyelid inflammation**
  - Easy to diagnose (only if more severe/significant).
  - Subtle initial signs and stages, often not recognised.
<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Advantages</th>
<th>Issues</th>
<th>Assessment parameters</th>
<th>Severe disease criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Refractory to standard disease treatments</strong></td>
<td>Disease shows lack of therapeutic response</td>
<td>▶ Definition of ‘standard treatment’ is critical.</td>
<td>Not established</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Not all the patients receive the same standard treatment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Refractoriness could be the consequence of inappropriate standard treatments.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Severity staging is needed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Discordance of symptoms and signs may be a pitfall.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Long-term anti-inflammatory therapies, topical and systemic, may induce adverse events.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Confocal microscopy</strong></td>
<td>May provide a non-invasive way to visualise high-resolution histologic-like patterns of the ocular surface structures.</td>
<td>▶ High resolution in vivo tissue examination.</td>
<td>Not established</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Minimally invasive.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Useful for counting inflammatory cells and investigating corneal nerves.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Provides overview of the whole ocular surface, including cornea, conjunctiva and limbus.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aberrometry</strong></td>
<td>Objective measurement of the time course of high-order aberrations may constitute an instrument to evaluate and manage patients with DED.</td>
<td>▶ Non-invasive system.</td>
<td>Not well established</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Gives rapid information about patient’s visual problems.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Useful for global definition of tear film conditions as a good indicator of tear film instability.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Easily repeatable, can be used to monitor therapy efficacy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ High sensitivity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inflammatory markers HLA-DR expression</strong></td>
<td>HLA DR class II antigen is an immune marker abnormally expressed by epithelial cells in inflammatory conditions.</td>
<td>▶ Minimally invasive sample collection of conjunctival imprints.</td>
<td>Used as a biomarker in clinical trials, not established in clinical setting</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Expressed by the most important cell population of the conjunctiva, that is, epithelial cells.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Large range of values; normal to severe dry eye.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Highly expressed in inflammatory and immune diseases.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Technique validated in several international multicentre trials with a central reading centre.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other inflammatory markers</strong></td>
<td>MMP9, cytokines, proteomics and Luminex assays.</td>
<td>▶ Study disease pathogenesis at the molecular level.</td>
<td>Not well established</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Minimal tear sample volumes needed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Possible multiple determinations for cytokines and MMPs.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Precise/objective determination of molecular quantity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Easy collection: possible to analyse eluate from Schirmer’s strips, cytology specimens, tear samples.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Not definitely established correlation with severity of the disease.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Not well defined role in specific dry eye pathogenic subgroups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Methods not yet very feasible for diagnostic purposes.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▶ Labs not available in all clinical centres (useful only for smaller phase 2 or phase 3 trials).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
Continued

### Table 2

<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Assessment parameters</th>
<th>Continuous grading</th>
<th>TBUT &lt;3 s</th>
<th>Severe disease criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBUT</td>
<td>Adequate measurement is difficult (partly subjective).</td>
<td>▶️ ◀️ ◀️ ◀️</td>
<td>▶️</td>
<td>▶️</td>
</tr>
</tbody>
</table>

**Tear film instability is one of the core mechanisms of DED that can initiate, amplify and potentially change the character of DED over time.**

These are clinical and biological markers or evaluations considered by the ODISSEY consensus panel to be indicative of DED, but are not yet sufficiently validated to establish diagnosis of severe DED.

DED, dry eye disease; HLA-DR, human leukocyte antigen-DR; MMP, matrix metalloproteinase; sec, second; TBUT, tear break-up time.

It is of note that filamentary keratitis is not considered as an additional determinant criteria in the case of Scenario C, as objective ocular symptoms determined by CFS have already been confirmed as mild (table 3). Similar to Scenario B, corneal sensitivity testing is not required, as the OSDI score is satisfactory.

### CONCLUSIONS

The ophthalmological field requires a reliable algorithm for patient-tailored evaluation of ocular surface damage, enabling definitive diagnosis of severe DED.\(^7\) However, reliable assessment of DED severity can be problematic due to several issues, including poorly standardised evaluation methods, non-correlation between disease severity and clinical/biological disease markers, and individual variability in symptomatology and disease signs. The vicious circle of DED pathogenesis, which can exacerbate the condition and facilitate merging or development of mechanistically distinct DED subtypes can further hinder accurate evaluation.\(^21\ 13\ 22\ 42\)

The ODISSEY scoring algorithm for severe DED diagnosis is a simple, easy-to-use and practical tool, which facilitates assessment of ocular surface damage and evaluation of disease severity. For the majority of DED patients who have a good symptom and sign correlation, OSDI and CFS are adequate to establish DED severity. For patients with symptom and sign dissociation, the evaluation of additional specific criteria are recommended to ascertain disease severity. It is hoped that use of this ‘bespoke’ diagnostic algorithm for evaluating severe DED will allow for targeted disease monitoring and treatment, and will also improve clinical trial outcome assessment.

Several systems for classifying DED severity already exist. The Triple Classification System bases severity on the continuing presence of symptoms, along with increasing signs of disease.\(^43\ 44\) The DEWS approach ranks DED severity on four levels, centred around simultaneous exacerbation of signs and symptoms.\(^5\) New Japanese DED diagnostic criteria now include symptomatology, and the presence of symptoms and signs is required for a diagnosis of ‘definite dry eye’, which correlates with more severe disease.\(^11\ 45\ 46\) All these classification systems require severe signs and severe symptoms for a diagnosis of severe disease. However, the ODISSEY scoring algorithm provides diagnostic pathways for patients with more complex discordant DED.

There are several limitations to the use of this model. The method of panel-based consensus is by its very nature not necessarily evidence based. The paucity of ‘gold-standard’ DED biomarkers with well-established criteria also impacts any attempt to standardise DED severity evaluation. Furthermore, the use of specific recommended assessments will heavily depend on local availability, training and cost. There is also an issue of pre-existing differences in definitions of dry eye. For example, the Japanese recognise a short break-up time, dry eye condition, characterised by very short TBUT and severe symptoms, but with minimal surface damage.\(^6\ 47\) This scenario is very similar to Scenario C of the algorithm presented in this paper. The
Table 3  Summary of determinant (ie, validated) and contributory (ie, indicative) diagnostic criteria and grading recommended by the ODISSEY panel to be used to establish severe DED in the case of symptom and sign discordance (ie, scenario A, B, or C)

<table>
<thead>
<tr>
<th>Criteria type</th>
<th>Evaluations</th>
<th>Scenario A</th>
<th>Scenario B</th>
<th>Scenario C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determinant</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Conjunctival staining (also conjunctivochalasis/conjunctival folds: severe degree)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Impaired visual function (photophobia, visual acuity modifications, low contrast sensitivity, or any combination of the above)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Filamentary keratitis</td>
<td>X</td>
<td>X</td>
<td>NA*</td>
<td></td>
</tr>
<tr>
<td>Blepharospasm</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hyperosmolality: &gt;328 mOsm/L</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Impression cytology: ≥grade 3 (Nelson Scale)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Corneal sensitivity: deeply impaired</td>
<td>X</td>
<td>NA‡</td>
<td>NA‡</td>
<td></td>
</tr>
<tr>
<td>Contributory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBUT &lt;3 s</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Aderometry</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Confocal microscopy</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Inflammatory markers: HLA-DR, MMP9, cytokines and proteomics</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

Criteria are ranked (highest to lowest) in order of perceived value for diagnosis. Inclusion of one or more accepted additional criterion is sufficient to establish DED as severe.

*Filamentary keratitis is not considered as an additional determinant criterion in Scenario C, as CFS has already established ocular surface damage to be low-level in this case.
†Adequate corneal sensitivity has already been confirmed by OSDI score in Scenarios B and C, and is thus not considered as an additional determinant criterion in these cases.
‡In Scenario C, when CFS is low, the TBUT test is considered as pre-requisite to reconfirm DED diagnosis (in light of primary criteria results).
MGD, meibomian gland disease, DED, dry eye disease, HLA-DR, human leukocyte antigen-DR, MMP, matrix metalloproteinase, TBUT, tear break-up time, sec, second, mOsm, millimole, L, litre, mm, millimetre, NA, not applicable, CFS, corneal fluorescein staining, OSDI, Ocular Surface Disease Index.

Japanese do not consider this condition severe, however, following the DEWS approach and the algorithm presented here, it would satisfy criteria for diagnosis as severe DED.

Nevertheless, by using a hierarchical approach to provide a range of acceptable marker options relevant for each patient it is hoped that, after extensive validation, this algorithm can be broadly applied across a range of clinical and geographical settings.

The next stage is to test the validity of the ODISSEY’s scoring algorithm in the context of clinical trials. It is hoped implementation of this tool will help to better define trial outcomes and accelerate clinical development of new treatments. Once validated, this algorithm will also aid the ophthalmologist in patient follow-up and treatment optimisation.

Acknowledgements The authors would like to thank Scinopsis Medical Writing for their help with this manuscript.

Collaborators Prof. Michael Lemp.

Contributors The authors are representative members of the European ODISSEY group and a thank you on behalf of the European ODISSEY group and a thank you on behalf of the European ODISSEY group meeting and content of this article.

 survives by Santen Pharmaceutical Co., Ltd. Santen has no input into the meeting and content of this article.

Competing interests CB is consultant for, or has received research grants from, Alcon, Allergan, Santen and Thea, PA is consultant for, or has research grant from, Alcon Italia, Allergan, Medivis, Santen, SIFI, Soof, Thea. MR is consultant for, or has received research grants from, Alcon, Allergan, Bausch & Lomb, Santen, and TRB Chemedica. ML is consultant to TearLab, TearScience, Merck, Santen.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/